Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually, that's an infinite increase ... much like getting our foot further in the door is infinitely better than not having any presence there.
Great PR, let's look for the 2's again!
Sure hope you were smart enough to buy at .003.
.016 up
On pace for... 300+ Million in volume?
I hope no one questions how quickly it could go back up to .02..
welll sheeeeeeeeeeeeeeeeeiiiit (anyone like The Wire?)
The blog at that site calls the product garbage... couldn't be further from the truth.
Good morning all, could be an extremely exciting day :)
We might need some news this week to add some logs to the fire..
Wish I could frame your post, Harleyboy, practically brought a tear to my eye...
you flop more than Manu Ginobli.. but at least you're on the right side for now :)
RedChip Announces Live Webcasts of Company Presentations Delivered At the 2009 Small-Cap Investor Conference, June 16th
CEOs of Participating Companies Will Deliver Presentations From 9 a.m. -- 5 p.m. At the Hilton Fort Lauderdale Marina On Tuesday, June 16th
ORLANDO, Fla., June 15, 2009 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. today announced that the CEOs and executive team presentations of 14 emerging small-cap and healthcare technology companies will be webcast live on Tuesday, June 16th, via www.RedChip.com beginning at 9 a.m. Eastern time. The corporate presentations, which offer an inside look into the industries and businesses of emerging growth companies, are being delivered during the 2009 RedChip Small-Cap Investor Conference being held in Fort Lauderdale, Florida. The event is being held in conjunction with Collaborative Communications Summit's Health Information Technology conference and features financial presentations by companies representing a wide range of sectors including Technology, Biotechnology, Energy, Consumer Goods, Telecommunications, and more. Company presentations will be archived at RedChip.com for later viewing and will be available for at least 90 days.
The RedChip investor conference will take place on Tuesday, June 16th from 8 a.m. to 5 p.m. -- at the Hilton Fort Lauderdale Marina (1881 SE 17th Street Causeway).
Participating investors will have the opportunity to meet one-on-one with the CEOs of presenting companies, while thousands of investors from across the world can view the conference online, watching the presentations live at RedChip.com on the day of the conference. In addition, RedChip TV(tm) will be on-site conducting interviews with CEOs. These executive interviews as well as the company presentations will be archived for later viewing at RedChip.com.
RedChip investor conferences are a nationally known forum for emerging small-cap companies to present their stories before hundreds of retail brokers, institutional brokers, fund managers, portfolio managers, accredited investors, and research analysts whose disciplined focus towards the small-cap markets represents their core investment strategies. Sponsors for RedChip's program include NASDAQ OMX; EquiSolve LLC; and National SEC Filing, Inc.
Presenting companies include the following:
RXi Pharmaceuticals Corporation (Nasdaq:RXII); Bioheart, Inc. (OTCBB:BHRT); Longwei Petroleum Investment Holding Ltd. (OTCBB:LPIH); ZAGG Inc. (OTCBB:ZAGG); Elephant Talk Communications, Inc. (OTCBB:ETAK); INVO Bioscience Inc. (OTCBB:IVOB); Celsius Holdings, Inc. (OTCBB:CSUH); China Education Alliance, Inc. (OTCBB:CEUA); Aethlon Medical, Inc. (OTCBB:AEMD); Dolphin Digital Media, Inc. (OTCBB:DPDM); The Quantum Group, Inc. (NYSE Amex:QGP); Nanostart AG (Frankfurt:NNS.F); PrivacyHarbor.com (Private); and Murdoch Security & Investigations, Inc. (Private).
Preregistration is required and seating is limited. To register online, please visit http://www.redchip.com/visibility/conferencePages/FTLauderdale2009/conferenceMain.asp or call 1-800-RedChip (733-2447), Ext. 127.
Preregistered attendees are also invited to a closing cocktail reception from 5:30 p.m. to 7 p.m. on June 16th at the Hilton Fort Lauderdale Marina.
About the Spring Collaborative Communications Summit HIT
The Spring CCS Health Information Technology Conference (http://www.ccsexpo.com/springccs.html) is a two-day conference that will provide an opportunity for investors and healthcare leaders to discover the latest trends and investment opportunities. The Collaborative Communications Summit is designed to help top-level executives, legislators, physicians, regulators and technologists come to grips with the swirling forces of health information technology change, policy development and changing business models. The CCS HIT provides an intimate, high level forum that facilitates open avenues of communication amongst executives and stakeholders in healthcare fostering the growth and adoption of HIT resulting in safer, more efficient and cost effective healthcare.
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida; with affiliate offices in Qingdao, China; Paris, London, Atlanta, Los Angeles and San Diego. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(tm), Shareholder Intelligence, Social Media and Blogging Services, and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/productsandservices.asp.
The RedChip Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2761
"Discovering Tomorrow's Blue Chips Today"(tm)
CONTACT: RedChip Companies, Inc.
Jon Cunningham
1-800-733-2447, Ext. 107
info@redchip.com
Top? What top? :)
Welcome to the WNBD party, everyone!
.021 coming
.0199 back up.. I think it happens this time.. hold on. eom
Man oh man.. maybe I'll put some of my WNBD profits into MOBL...
Love the latest PR.. it's alllll about brand awareness right now for WNBD:
Winning Brands Chooses Indianapolis for First Launch Into Convenience Stores
Friday 06/12/2009 5:00 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
WNBD 0.0195 71.05%
As of 1:09 PM ET 6/15/09
Winning Colours Stain Remover Targets Greater Indianapolis for Initial Wave of 100 C-Stores
Winning Brands Corporation (Pink Sheets: WNBD) (Frankfurt: WMU.F), manufacturer and marketer of advanced eco cleaning solutions, announced today that the race was on to implement its new marketing program called "The Local 100." The aggressive program identifies specific U.S. urban areas in which Winning Brands intends to establish intense local product placement for its breakthrough stain removing solution called Winning Colours Stain Remover. The "Local 100" method focuses on attaining 100 points of sale over any specified 6 week period in an urban market. Indianapolis is the first target market for the program. July 31st is the date set by which to have Winning Colours Stain Remover available in 100 stores in greater Indianapolis.
(Photo: http://www.newscom.com/cgi-bin/prnh/20090612/LA31678)
Winning Brands CEO Eric Lehner explains the context - "The Local 100 program is designed to create 'hot zones' where Winning Colours Stain Remover can gain traction through sheer exposure. We are focusing on the convenience store category in our 'Local 100' programs for several reasons. Firstly, there are nearly 140,000 such outlets in America today; in other words, they are everywhere. Secondly, within this group, there is a healthy variety of suitable field teams with whom to develop custom fulfillment arrangements. Thirdly, a higher than average proportion of convenience stores are independently owned. This lets the pace of our progress match our own initiative because convenience stores can react faster than conventional retail chains for such a program."
Winning Colours Stain Remover has come to the attention of industry watchers because of Winning Brands' plan to create the world's favourite stain removing solution. Winning Brands Senior Vice-President, Lorne Kelly, remarks, "Customers have become quite enthusiastic about Winning Colours Stain Remover, but we are business realists. Landing on the store shelves across the country is what we need to accomplish as the business method. Then those hot zones can emerge and distribution consolidates into regions. What we must achieve is that Winning Colours Stain Remover is known across America, used across America and becomes its favourite stain removing product. We want to reach the point that people will connect us to the simple but powerful premise - 'Got Stains? Try this!' Our determination is fuelled by the testimonials we receive. Winning Colours is terrific for the millions of stains that happen every day."
The first Local 100 program will feature custom designed Winning Colours Stain Remover 12-pack displays that fit easily on counters. The display packs contain pocket-sized 4 oz bottles that fit into purses, auto glove compartments, tool kits, kitchen drawers, and many situations where space is limited or portability matters. The Manufacturer's Suggest Retail Price (MSRP) for the mini-bottle of concentrate is $3.99. Winning Colours is known to be highly dilutable as a multi-cleaner. The 4 oz bottle can yield between 40-80 ounces of multi-cleaner by mixing with plain water or can be used full strength for stain shots. At the end of July Winning Brands will add the names, addresses and photographs of each of its 100 new Indianapolis outlets to the Winning Brands' Store Locator page at www.WinningBrands.ca.
Mr. Lehner concludes, "The bottom line is that Winning Colours Stain Remover is a universal product. Few products on the market have as many ways in which to be distributed as Winning Colours. This is an example of that fact. We can grow categories; home improvement, grocery, convenience stores, office supply stores, pet stores, wine stores - there are as many ideas as there are stains."
ABOUT WINNING BRANDS CORPORATION: Winning Brands Corporation is a manufacturer and marketer of eco-responsible solutions including its lead brand, Winning Colours Stain Remover. The innovative stain remover and multi-cleaner is targeted to become the world's favourite stain removing solution because of its remarkable skin-friendliness, ease of use and versatility. TrackMoist Dust Suppressant is gaining fans in all sectors of motorsports for its ability to dramatically conserve water and improve track performance. Additional brands include KIND Laundry Products, CLEAN1 Spray, and SMART Wet Cleaning Solutions.
Certain statements in this news release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Winning Brands Corporation (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; and (iii) competitive factors and developments beyond the Company's control. TrackMoist, KIND and CLEAN1 is a trademark of Niagara Mist Marketing Ltd., subsidiary of Winning Brands Corporation. Winning Colors/Winning Colours is a registered trademark of Niagara Mist Marketing Ltd. SMART is a trademark of Solvent Free Solutions Inc.
INVESTOR RELATIONS: E & E Communications
Paul Knopick (949)707-5365
News@WinningBrands.ca
PRODUCT INFORMATION: Winning Brands Corporation
11 Victoria Street, Suite 220A, Barrie, Ontario, Canada L4N 6T3
(866) 722-3542
CustomerService@WinningBrands.ca
SOURCE Winning Brands Corporation
http://www.WinningBrands.ca
yeah 60% green is horrible. ugh! :)
Look at the sticky note.
you are the master
do it, I dare ya.
I suggest the stock master gets his own L2..
That's awesome, but I prefer this one :)
How do the futures look this morning? thanks in advance
I have a suspicion that some here will be waking up just before 5 am tomorrow morning :)
Like shorts and bashers chasing the WNBD stock price tomorrow
http://vimeo.com/4862670
Someone say Colorado River? Just took a trip out west and got some footage of the river... take a look
http://vimeo.com/4961112
Believe it or not, I had a 4 oz bottle of WC with me on the trip :)
Just wanted to drop in and say congrats to all.. still long and strong since late '07.
Also... just wanted to commend Harley boy for promoting WNBD to the masses... ;)
Posted by: Harleyboy Date: Saturday, June 13, 2009 10:38:06 AM
In reply to: None Post # of 95471
WNBD went crazy on Friday, I expect more the coming week...and month. Pretty good looking pink if you are into that type of deal. Great products, solid company...looking for USA expansion.
Yes, you can see Joyce's excitement in the way he wrote this one...
we're SO CLOSE!
Wow... great letter, IMO!
Aethlon Medical Inc. has added a news release to its Investor Relations website.
Title: Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
Date: 6/10/2009 7:47:00 AM
For a complete listing of our news releases, please click here
SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC
Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A.
Joyce has issued the following letter to shareholders.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
To our Shareholders:
On March 25th we announced a data driven strategy to improve Hepatitis-C
virus (HCV) cure rates by combining the benefit of our Hemopurifier(R) with
the interferon-ribavirin standard of care (SOC) administered to HCV-infected
patients. Since disclosing our strategy, a candidate business partner has
introduced us to clinical data that validates the mechanical removal of HCV
through blood filtration in combination with SOC therapy can increase HCV cure
rates by greater than 50%. Amazingly, the data also indicates that only small
levels of viral filtration administered at the outset of SOC therapy are
required to outperform the leading adjunct drug candidate, which represents a
significant value component of a publicly traded company whose market
capitalization exceeds $5 billion. If you are just learning about Aethlon
Medical, our Hemopurifier(R) is a first-in-class medical device that
selectively removes infectious viruses and immunosuppressive proteins from the
bloodstream. In HCV care, the Hemopurifier(R) inhibits viral replication
through selective adsorption of circulating HCV and augments the immune
response by removing toxic proteins shed from HCV to kill-off immune cells.
More than ever, I believe the scientific principles underlying our
Hemopurifier(R) will inevitably change the landscape for treating infectious
disease and cancer. As we transition beyond the research and development
phase of operations, our initial commercialization efforts related to
therapeutic Hemopurifier(R) applications will focus on delivering our
technology into India and other practitioner-driven medical device markets.
Pending the outbreak of a pandemic or bioterror threat, our primary focus in
these markets will be the treatment of HCV. Such focus is driven by previous
Hemopurifier(R) treatment outcomes, the validation that viral filtration
increases cure rates, and the magnitude of the HCV treatment opportunity.
Our goal in HCV care is to increase patient cure rates up to 90%. We
envision two pathways to reach this goal:
1. Our Hemopurifier(R) as an adjunct treatment to enhance the benefit of
SOC therapy; or
2. Our Hemopurifier(R) in combination with a candidate therapy to replace
SOC therapy.
The achievement of our goal would significantly impact the HCV treatment
industry as SOC therapy succeeds in providing sustained viral responses (SVR)
in only 30% to 50% of patients who initiate treatment. HCV infection is
considered cured when a SVR of undetectable viral load is maintained more than
six months after completing treatment. Prior to discussing the clinical
rationale supporting our treatment goals, I want to clarify the magnitude of
the HCV treatment opportunity.
It is estimated that nearly 180 million people worldwide, or approximately
3% of the world's population, are infected with HCV. To provide perspective,
this represents a patient population approximately 5-6 times larger than those
infected with HIV/AIDS and over 100 times larger than the population of end
stage renal disease (ESRD) patients who require kidney dialysis. However,
unlike kidney dialysis and HIV therapeutics, we actually have the opportunity
to participate in curing HCV-infected individuals. The global market for
therapies to treat HCV is projected to reach $9.1 billion by 2015, and in the
United States, the annual cost of advanced liver disease resulting from HCV
infection is anticipated to jump to $85 billion in the next two decades. As a
result, Medicare costs are anticipated to soar 500%, from $5 billion to $30
billion. As the stakes to treat HCV are high, the competition for new drugs
is intense with more than sixty treatment candidates reported to be in
development. As we target the use of our Hemopurifier(R) as a drug
enhancement device in HCV care, we are positioned to improve treatment
outcomes as an adjunct to both SOC therapy and new drug candidates that evolve
to challenge SOC therapy in the marketplace.
Significant challenges exist for drugs seeking to supplant SOC therapy, as
new candidates must demonstrate substantially greater patient benefit in order
for the medical community to consider discontinuing administration of the SOC
treatment regimen. As an example, Albuferon, an HCV treatment candidate from
Human Genome Sciences (HGSI), recently demonstrated phase III treatment
outcomes comparable to SOC therapy with half the number of required
injections. As a result, the value of HGSI shares was reduced by 57% the day
the study data was released. I can't help but wonder how Albuferon might have
performed in combination with our Hemopurifier(R)? Regardless, a drug
candidate wishing to supplant SOC therapy in the market will need to Bob
Beamon (surpassed world long jump record by almost two feet at the 1968
Olympics) beyond the capabilities of SOC therapy.
For this reason, the primary strategy for most HCV drug candidates is to
incrementally improve treatment outcomes as an adjunct to SOC therapy. The
challenge facing these candidates is the effect of stacking new drug toxicity
on top of established SOC toxicity, which is known to trigger fatigue, bone
marrow suppression, anemia and neuropsychiatric effects. Many patients fail
SOC therapy because they are unable to endure the toxicity of the 24-48 week
regimen on its own. Based on clinical data, Telaprevir, a 3x-day oral drug
from Vertex Pharmaceuticals is considered the leading adjunct candidate based
on outcomes of a recent phase II study, which documented that 51% of patients
that previously failed SOC had a sustained virologic response (SVR) when
retreated with SOC and Teleprevir in combination. When considering that only
14% of patients in the study control arm responded to SOC alone, there is
certainly valid justification for Telaprevir to be considered the lead adjunct
drug candidate by the medical and the financial community. This is reinforced
by the reality that Telaprevir represents a significant value component of
Vertex (VRTX), which as I write this letter is valued at more $5 billion in
the public markets. In regards to deal values in the HCV space, VRTX paid
almost $400 million in March to acquire ViroChem, a drug developer with two
experimental stage HCV drugs. TheStreet.com, who provides excellent HCV market
coverage, reports the following on the Telaprevir clinical outcome; "The data
keeps Telarevir ahead of its hepatitis C rivals because no other drug has yet
shown the ability to improve the cure rates for both patients new to therapy
as well as those who have failed prior therapy." The key phrase in that
statement is "no other drug".
I suspect most individuals following the HCV treatment industry are not
yet aware of a medical device study that demonstrated the mechanical removal
of HCV through blood filtration outperforms Telaprevir as an adjunct to SOC
therapy. The insight provided by this clinical validation should
significantly benefit our endeavors. In a 63 patient study conducted in
Japan, Asahi Kasei Kuraray Medical (Asahi) demonstrated that double filtration
plasmapheresis (DFPP) when administered at the outset of SOC therapy provided
a 77.8% SVR in HCV-infected patients. In patients who previously failed SOC,
DFPP treatment provided an average SVR of 71.4% versus the 51% previously
referenced in Telaprevir clinical studies. On average, each patient in the
Asahi study received three DFPP treatments each lasting 3.14 hours. In the
study, DFPP was administered once daily for three consecutive days at the
outset of SOC therapy and provided an average viral load reduction of 26.1%
during each treatment period. Amazingly, the 71.4% and 77.8% cures rates were
achieved without any additional DFPP during the remaining SOC treatment
regimen. As a result of DFPP treatment outcomes, Asahi has advanced DFPP
beyond treatment candidate status to actively marketing the treatment in Japan
as the V-RAD system, which Asahi derives from the phrase "Virus Removal and
Eradication by DFPP". Additional information can be accessed online at:
www.v-rad.jp/en/index.html. I shall keep my comments directed towards the
science underlying the V-RAD system and not the animation you will encounter
at this website. Regardless, the website is quite informative.
However, there are significant limitations for DFPP as compared to our
Hemopurifer(R). Like other approaches to therapeutic filtration, DFPP relies
on multiple pumps and filters to indiscriminately remove particles by molecule
size. For this reason, DFPP also extracts particles beyond HCV that are
required for patient health. The safety profile of DFPP can be further
diminished by the need for replacement fluids. In combination, these factors
limit the time an HCV-infected patient can be exposed to DFPP treatment.
The advantages of our Hemopurifier(R) as compared to DFPP include the
following:
1. The Hemopurifier(R) provides a greater reduction of HCV from
circulation during treatment. Our data resulting from over 20 HCV
treatments indicates an average viral load reduction of 41% during
four-hour treatment applications of the Hemopurifier(R).
2. The Hemopurifier(R) augments the immune response by removing toxic
proteins shed from HCV to kill-off immune cells. These proteins are too
small to be captured by DFPP.
3. The Hemopurifier(R) is designed to selectively capture HCV and
immunosuppressive proteins versus the indiscriminate removal of
particles by DFPP.
4. The Hemopurifier(R) is one single-use disposable cartridge versus the
requirement for two cartridges and multiple pumps with DFPP.
5. The selective ability of the Hemopurifier(R) to capture targeted
viruses and immunosuppressive proteins (versus the removal of needed
blood components) allows for a continuous Hemopurifier(R) treatment
strategy to rapidly reduce viral load to low to undetectable levels.
Thus, increasing the likelihood that HCV infected individual can be
cured by SOC therapy.
While we believe our Hemopurifier(R) has obvious advantages over the DFPP
system, I wish to expand on point #5 as it provides a foundation to support
our treatment goal of increasing HCV cure rates up to 90%. Based on published
treatment literature, it is well established that patients who initiate SOC
and achieve a rapid viral response (RVR) have significantly higher cure rates.
RVR is defined as undetectable viral load at day 30 of SOC treatment. In
fact, published literature indicates the small percentage of patients who do
achieve a RVR have cure rates that range from 86-92%. Based on our
Hemopurifier(R) data, we believe it is possible to achieve undetectable levels
of HCV in week one of SOC therapy, not day 30. Based on data analyzed from
four-hour Hemopurifier(R) treatments, we project that a patient with a high
viral load of 7 million iu/ml might be reduced to undetectable HCV levels
after approximately three days of continuous Hemopurifier(R) treatment. This
corresponds to a 4.06 log reduction or a 11,000-fold decrease in viral load.
An HCV patient with a moderate viral load of 2 million iu/ml would be
projected to reach undetectable levels in approximately 2.5 days of continuous
treatment. Such outcomes would position us to achieve our 90% cure rate goal
and may allow for decreased dosages and duration of SOC therapy.
To leverage our opportunity in HCV care, we are pursuing strategic
relationships that will broaden our ability to commercialize in practitioner
driven markets, or accelerate our clinical opportunities in the U.S. and
European Union. Additionally, we have responded to a grant opportunity to
advance a diagnostic based Hemopurifier(R) and have been working on a
candidate clinical protocol for a grant proposal related to the use of our
Hemopurifier(R) as an adjunct cancer treatment to remove tumor secreted
exosomes known to suppress the immune system of cancer patients. The data
from these cumulative activities, including recent HIV and HCV treatment
outcomes, will cause us to update the investigational device exemption (IDE)
we have previously filed with the FDA related to use of our Hemopurifier(R) as
a treatment countermeasure against bioterror and pandemic threats. In this
regard, we were recently advised that we were a candidate being considered for
a contract award from the Biomedical Advanced Research and Development
Authority (BARDA). This was related to a multi-agency contract solicitation
known as DMID-NIAID-NIHAI20080022BARDA. We have since been advised by BARDA
that they will not be granting awards under this solicitation. BARDA has
encouraged to update our data collected since our original submission and
resubmit a new proposal to a BARDA specific contract solicitation known as
BAA-BARDA-09-34. As we believe our Hemopurifier(R) represents the most
advanced broad-spectrum treatment strategy to protect our military and
civilian populations from viruses considered bioterror and pandemic threats,
we plan to provide BARDA our new submission no later than July 31st.
Regardless of these opportunities, our primary focus moving forward will be
the treatment of Hepatitis-C.
On behalf of our dedicated team at Aethlon Medical, I thank you for your
continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
You seem to be the only one worried that they STOPPED all production after that single, half truckload of product. You ask him and make a fool of yourself.
Let me help you... I'll just bold the rest of what you pasted. You're welcome.
BARRIE, ON--(MARKET WIRE)--Dec 28, 2007 -- Winning Brands Corporation (Other OTC:WNBD.PK - News) www.WinningBrands.ca reports that initial production of its Winning Colours® Stain Remover was blended on schedule and without incident at the previously announced new manufacturing facility in Grand Rapids, Michigan in December as forecast. Surefil LLC of Grand Rapids, Michigan www.Surefil.com, a top rated custom manufacturing facility, was able to produce the first 1/2 truckload batch on December 27th in a fraction of the previously required time, for packaging January 2nd and delivery to the distribution pipeline during the first week of January. This initial production was earmarked for use by Home Depot Canada to fill new custom metal aisle display stands of Winning Colours® Stain Remover for testing at 100 stores; a merchandising concept requiring 9,240 32oz bottles. The M.S.R.P. value of these bottles to consumers is $91,938.00. Other stores to be announced in due course are also testing a smaller number of these new merchandising displays
Um, no... APPARENTLY that's what they initially produced for the Canada HD racks... AS STATED in referenced PR.
Give us a break. It's old.
It can't be more than half a truckload? C'mon crashman, you're ridiculous soemtimes.. you can do better than that.
Why don't you e-mail him and ask for a yes or no?
Thanks in advance!
Hey guys, wanted to share this with you... some footage from my disc golf trip out west. Unfortunately, there's not any actual disc golf footage yet, but some beautiful scenery. If you like what you see you can subscribe to the channel and watch for when I finish editing the disc golf stuff. Some absolutely gorgeous courses out there.
http://vimeo.com/channels/inthewest
With the PPS this low, the lowes PR might actually affect it now.